Joseph Todisco serves as the Chief Executive Officer at CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. With a strong background in the pharmaceutical and healthcare industries, Todisco has been instrumental in guiding CorMedix through various stages of growth and development. Under his leadership, the company has made significant strides in advancing its product pipeline, particularly with its lead product candidate, DefenCath™, which is aimed at preventing infections associated with central venous catheters. Before joining CorMedix, Todisco held several key executive positions that have shaped his expertise in the sector. He previously served as the President and CEO of MetaStat, Inc., where he led the company's strategic direction and oversaw its transition from a research-focused entity to a more commercially oriented organization. His career also includes significant roles at major pharmaceutical companies such as Bristol-Myers Squibb and Johnson & Johnson, where he gained extensive experience in product development, regulatory affairs, and market strategy. Todisco's educational background includes a Bachelor of Science degree in Pharmacy from the University of Pittsburgh and an MBA from the Wharton School of the University of Pennsylvania. In his role at CorMedix, Todisco is responsible for steering the company's overall strategy, fostering innovation, and ensuring the successful execution of clinical trials and regulatory milestones. His leadership has been pivotal in securing partnerships and funding to support the company's mission. Todisco's vision for CorMedix is to become a leader in the development of novel therapies that address critical medical needs, and his dedication to this goal continues to drive the company forward.